Jefferies Initiates Silence Therapeutics(SLN.US) With Buy Rating, Announces Target Price $40
Silence Therapeutics Analyst Ratings
H.C. Wainwright Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $75
Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $49
Morgan Stanley Reaffirms Their Buy Rating on Silence Therapeutics (SLN)
Analysts Offer Insights on Healthcare Companies: Silence Therapeutics (SLN), Pharvaris (PHVS) and Stevanato Group (STVN)
Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $49
Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $49
BMO Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $67
Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $49
Chardan Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $55
Analysts Offer Insights on Healthcare Companies: Danaher (DHR), Silence Therapeutics (SLN) and Exscientia Plc (EXAI)
Silence Therapeutics (SLN) Receives a Buy From Morgan Stanley
Silence Therapeutics (SLN) Gets a Buy From Morgan Stanley
Morgan Stanley Raises Price Target on Silence Therapeutics to $49 From $45, Keeps Overweight Rating
Silence Therapeutics Analyst Ratings
Silence Therapeutics Analyst Ratings
Silence Therapeutics Analyst Ratings
Optimistic Buy Rating for Silence Therapeutics Based on Divesiran's Market Potential and Positive Clinical Outlook
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Intuitive Surgical (ISRG) and Silence Therapeutics (SLN)
No Data
No Data